#COVID-19 vaccine

Research identifies most common symptoms and potential subgroups with the aim of improving future diagnostics and treatment.

Vaccine type, older age, male sex and especially smoking were associated with lower antibody responses.

Study suggests adults with both the sleep disorder and COVID-19 may benefit from clinical monitoring.

A booster targeting Omicron SARS-CoV-2 variant produced a broader immune response than one targeting variants similar to original strain.

For the millions who are more vulnerable to COVID, reliable data remains important for assessing safety.

Study findings suggest people with chronic liver disease should be prioritized for booster shots.

People 65 and older and immunocompromised people can get a second bivalent booster; most unvaccinated people now need only one initial shot.

NIH-funded study suggests need to boost CD8+ T cell response after infection.

People without insurance will need to either pay full price, seek free or low-cost vaccines from community clinics or go without.

Overall, people with and without HIV had low and comparable rates of severe breakthrough illness.

Increased protection against hospitalization or death was seen regardless of age or history of previous boosters.

Monoclonal antibodies used to prevent COVID-19 in immunocompromised people aren’t active against new virus variants.

Data suggest skepticism and misinformation surrounding COVID vaccines now threatens other public health priorities.

While regular boosters may help keep vulnerable people out of the hospital, annual boosters might not be necessary for everyone.

Vaccines are tested for safety, but like all medical products, they can sometimes cause side effects.

NIAID-supported research sheds light on why healthy people of the same age respond differently to vaccines.